|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Trypanosoma_cruzi
|
|
gptkbp:activities
|
inhibits trypanothione reductase
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:Argentina
gptkb:Brazil
gptkb:United_States
|
|
gptkbp:brand
|
Benznidazol
Rochagan
|
|
gptkbp:class
|
nitroimidazole
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
|
|
gptkbp:composed_of
|
nitration of 2-methyl-1 H-imidazole
reduction of nitro group
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
severe liver disease
hypersensitivity to benznidazole
|
|
gptkbp:discovered_by
|
1970s
|
|
gptkbp:dissolved
|
soluble in water
soluble in ethanol
|
|
gptkbp:duration
|
30 days
60 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
benznidazole
|
|
gptkbp:ingredients
|
C12 H15 N5 O4 S
|
|
gptkbp:interacts_with
|
gptkb:phenytoin
gptkb:cimetidine
gptkb:phenobarbital
gptkb:warfarin
|
|
gptkbp:invention
|
patented
generic available
|
|
gptkbp:is_atype_of
|
P01 C B01
|
|
gptkbp:is_used_for
|
Chagas disease
|
|
gptkbp:lifespan
|
12 hours
|
|
gptkbp:marketed_as
|
gptkb:Chemo_Research_S._L.
|
|
gptkbp:related_to
|
metronidazole
nitazoxanide
|
|
gptkbp:research_focus
|
antimicrobial resistance
treatment of leishmaniasis
treatment of Trypanosoma cruzi
|
|
gptkbp:rounds
|
urine
|
|
gptkbp:safety_features
|
Category C
not recommended during pregnancy
|
|
gptkbp:side_effect
|
fatigue
nausea
rash
|
|
gptkbp:treatment
|
oral
topical
|
|
gptkbp:type_of
|
163252-24-3
|